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Abstract
Background: Smoking paradoxically increases the risk of small-for-gestational-age (SGA) birth but protects against
preeclampsia. Some studies have reported a “U-shaped” distribution of fetal growth in preeclamptic pregnancies,
but reasons for this are unknown. We investigated whether cigarette smoking interacts with preeclampsia to affect
fetal growth, and compared levels of soluble fms-like tyrosine kinase-1 (sFlt-1), a circulating anti-angiogenic protein,
in preeclamptic smokers and non-smokers.
Methods: From a multicenter cohort of 5337 pregnant women, we prospectively identified 113 women who
developed preeclampsia (cases) and 443 controls. Smoking exposure was assessed by self-report and maternal hair
nicotine levels. Fetal growth was assessed as z-score of birthweight for gestational age (BWGA). sFlt-1 was
measured in plasma samples collected at the 24-26-week visit.
Results: In linear regression, smoking and preeclampsia were each associated with lower BWGA z-scores (b = -0.29;
p = 0.008, and b = -0.67; p < 0.0001), but positive interaction was observed between smoking and preeclampsia (b
= +0.86; p = 0.0008) such that smoking decreased z-score by -0.29 in controls but increased it by +0.57 in
preeclampsia cases. Results were robust to substituting log hair nicotine for self-reported smoking and after
adjustment for confounding variables. Mean sFlt-1 levels were lower in cases with hair nicotine levels above vs.
below the median (660.4 pg/ml vs. 903.5 pg/ml; p = 0.0054).
Conclusions: Maternal smoking seems to protect against preeclampsia-associated fetal growth restriction and may
account, at least partly, for the U-shaped pattern of fetal growth described in preeclamptic pregnancies. Smoking
may exert this effect by reducing levels of the anti-angiogenic protein sFlt-1.
Background
Preeclampsia, a hypertensive disorder that occurs in 2-
7% of pregnancies, is an important cause of fetal and
maternal morbidity and mortality [1]. Paradoxically,
while maternal cigarette smoking increases the risk of a
number of pregnancy complications, including miscar-
riage, preterm birth and small-for-gestational-age (SGA)
birth, smoking has consistently been shown to be asso-
ciated with a ~30% reduction in the risk of preeclampsia
[2,3]. The mechanism for this protective effect is
unclear, but may involve direct effects of smoking
byproducts nicotine or carbon monoxide in inhibiting
placental cytokine production, placental vascular con-
striction or oxidative stress [4,5], factors that have been
implicated in the pathophysiology of preeclampsia [6].
Furthermore, it was recently reported that both in nor-
mal and preeclamptic pregnancies, smoking is associated
with lower maternal plasma concentrations of soluble
fms-like tyrosine kinase-1 (sFlt-1) [7], a circulating anti-
angiogenic protein that induces endothelial dysfunction * Correspondence: susan.kahn@mcgill.ca
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women who subsequently develop preeclampsia [8].
In preeclamptic pregnancies, fetal growth has been
described as having a “U-shaped” distribution, with an
increased risk of both low birthweight and high birth-
weight babies [9]. In a case-control study nested within
a large multicenter cohort of pregnant women whose
primary aim was to evaluate the link between thrombo-
philia and preeclampsia, we performed secondary,
hypothesis-generating analyses to assess whether mater-
nal cigarette smoking, measured by self-report and by
hair nicotine levels, modifies the association between
preeclampsia and fetal growth. In addition, we examined
the relationship between plasma sFlt-1 levels, smoking
and preeclampsia.
Methods
The Montreal Preeclampsia Study [10] is a case-control
study nested within a prospectively recruited cohort of
5337 pregnant women who were participants in the
Montreal Prematurity Study, a large multicenter study
on causal pathways of preterm birth [11]. At the time of
providing informed consent for the preterm birth study,
the preeclampsia study was explained and women were
asked to provide signed informed consent on a separate
consent form. Before both studies were started, they
received approval by the research ethics committees of
the four participating hospital centers (Hôpital St. Luc;
Hôpital Maisonneuve Rosemont; Royal Victoria Hospital
and Jewish General Hospital [approved jointly by McGill
University Faculty of Medicine institutional review
board]) Our research conformed to the Helsinki
Declaration (http://www.wma.net/en/30publications/
10policies/b3/17c.pdf) and to local legislation.
Recruitment of cohort and follow-up to time of delivery
Patients and study setting
Trained research assistants approached consecutive
pregnant women at the time they presented for routine
ultrasound examination (most subjects), prenatal blood
drawing, or first- or second-trimester obstetric clinic vis-
its at four large maternity hospitals affiliated with
McGill University or l’Université de Montréal in Mon-
tréal, Canada. Women aged ≥18 years at the expected
date of delivery who spoke and understood French or
English and had a singleton fetus were eligible for enrol-
ment in the study. Women with severe chronic illness
(other than hypertension, asthma or diabetes) requiring
ongoing treatment, placenta previa, history of incompe-
tent cervix diagnosed in a previous pregnancy, impend-
ing delivery, or a fetus affected by a major anomaly
were excluded. Among these excluded women, reasons
for exclusion and data on maternal education were
recorded whenever possible.
Study visit at 24-26 weeks
Women who consented to participate were asked to
return for a study visit at 24-26 weeks of gestation to
obtain data on sociodemographic characteristics, medi-
cal, obstetric and family history, and cigarette smoking.
Subjects were asked if they had ever smoked, if they had
smoked (defined as one or more cigarettes per day) dur-
ing the pregnancy, and if so, the average number of
cigarettes smoked per day.
After the interview, non-fasting blood samples were
obtained by venipuncture and immediately placed on
ice. Samples were centrifuged, and plasma was aliquoted
into cryovials that were frozen at -80°C.
Identification of cases of preeclampsia and selection of
control subjects
Cohort women were followed until delivery. During the
admission for delivery, each study woman identified as
having had hypertension or preeclampsia during preg-
nancy or after delivery underwent a detailed interview
and chart review by trained study staff to assess whether
diagnostic criteria for preeclampsia were met. Pree-
clampsia was diagnosed according to the 1997 Canadian
Hypertension Society criteria and further classified as
severe or early onset (Table 1) [12]. All cases of pree-
clampsia (n = 113) were independently verified by two
study investigators (SK and HM).
Primarily for recruiting convenience, controls (n =
443) were study women who delivered at the same hos-
pital closest in calendar time to a case, but did not have
preeclampsia. As controls partially overlapped with
those of the concurrently running preterm birth study
[11], 3-4 eligible controls were available per case of pre-
eclampsia. Study women who had onset of hypertension
during pregnancy but did not meet criteria for pree-
clampsia were ineligible to be cases or controls and
were excluded from all analyses.
Postpartum procedures for cases with preeclampsia and
control subjects
After delivery, study staff collected data from the
mother’sa n di n f a n t ’sh o s p i t a lc h a r ta n db yi n t e r v i e w
on infant birthweight, sex, placental weight, gestational
age and pregnancy course since the 24-26 week study
visit.
Infant birthweight and placental weight were recorded
as the weights obtained in the delivery room. Gesta-
tional age was determined using both the subject’sl a s t
menstrual period (LMP) as well an ultrasound estimate
usually obtained at 16-20 weeks gestation. If the gesta-
tional age estimates using the two methods differed by
more than 7 days, the ultrasound estimate was used;
otherwise, the LMP estimate was chosen. During the
postpartum interview, subjects were asked if they had
smoked cigarettes (defined as one or more cigarettes per
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number of cigarettes smoked per day.
Laboratory analyses
After delivery, cases and controls had a small amount of
maternal hair cut from the posterior scalp, sealed in a
labeled envelope and sent in batches to Dr. Koren’s
laboratory in Toronto to test for nicotine concentra-
tions, using previously described techniques [13]. Results
are expressed in nanograms of nicotine per milligram of
hair.
Plasma samples of cases and controls were retrieved
and thawed. sFlt-1 concentration was measured in Dr.
Genest’s laboratory using commercial ELISA kits from
R&D systems (Minneapolis, MN). Results are expressed
in pg/ml. The sFlt assay is specific for human sFlt-1,
with sensitivity of 5 pg/ml. As reported by the manufac-
turer, intra-assay and inter-assay coefficients of variation
are 3.2% and 5.5%, respectively.
All laboratory analyses were performed blindly with-
out identifying the source of each specimen as a case or
a control.
Statistical analysis
Data on demographic and medical characteristics, self-
reported cigarette smoking, pregnancy outcome, and
hair nicotine and plasma sflt-1 concentrations were
compared in cases and controls using t-tests for contin-
uous variables and chi-square tests for categorical vari-
ables. Hair nicotine and plasma sFlt-1 were examined
both as continuous and quantile (divided at the median
and by quartiles, respectively) variables. A P value of <
0.05 was considered statistically significant.
Fetal growth was assessed on a continuous scale as the
z-score of birthweight for gestational age (BWGA),
using the following formula: z = (observed birthweight -
mean birthweight)/SD, where mean and SD were based
on published Canadian population-based standards, stra-
tified by infant sex and gestational age in completed
weeks [14]. SGA and LGA births were defined as having
birthweight below the 10
th percentile and above the 90
th
percentile, respectively, using the same Canadian popu-
lation-based standards used to obtain the BWGA z-
scores.
Multiple linear regression was used to test associations
between measures of maternal tobacco smoke exposure,
preeclampsia, and z-score of BWGA. Models were con-
structed in which the dependent variable was fetal growth
represented by z-score of BWGA, and the independent
variables were preeclampsia, maternal tobacco smoke
exposure (self-reported smoking status, or log-transformed
hair nicotine concentration), and an interaction term for
preeclampsia and smoking exposure. As the distribution
of hair nicotine was right skewed, this variable was log-
transformed (natural log) to normalize the distribution. In
order to retain 0 values, we added a constant (0.1) that
best normalized the distribution after log-transformation.
Because birthweight and fetal growth are known to be
influenced by placental weight, we also constructed
models adjusted for placental weight, represented by the
z-score of placental weight for gestational age (PWGA)
using the following method, described by McNamara
[15,16]: z = (observed placental weight at a given gesta-
tional age - mean placental weight for that gestational
age)/SD, where mean and SD were based on singleton
deliveries (excluding infants with congenital anomalies)
between 1978 and 2001 in the McGill Obstetrical and
Neonatal Database [17], stratified by ultrasound-con-
firmed gestational age.
Table 1 Classification of preeclampsia among cases (N = 113)
Total Early-onset
b Severe
c
Canadian Hypertension Society classification
a
Gestational hypertension with proteinuria without adverse conditions 12 (11%) 3 (8%) 0 (0%)
Gestational hypertension with proteinuria with adverse conditions 49 (43%) 16 (46%) 19 (59%)
Gestational hypertension without proteinuria with adverse conditions 49 (43%) 14 (40%) 10 (31%)
Chronic hypertension with superimposed preeclampsia 3 (3%) 2 (6%) 3 (10%)
TOTAL 113 (100%) 35 (100%) 32 (100%)
a Diagnostic criteria used for preeclampsia and non-preeclamptic hypertensive disorders of pregnancy were adapted from the 1997 Report of the Canadian
Hypertension Society Consensus Conference [12]. Gestational hypertension was defined as diastolic hypertension (≥ 90 mm Hg) on two occasions at least 4-6
hours apart that developed after 20 wks gestation. Proteinuria was defined as protein excretion of ≥ 0.3 g/day in 24-hour urine collection or positive dipstick
result ≥ 2+. Adverse conditions were defined as convulsions (eclampsia), diastolic pressure > 110 mm Hg, platelet count < 100,000 × 10
9/L, oliguria, protein
excretion ≥ 3 g/day, pulmonary edema, elevated liver enzymes, severe nausea and vomiting, frontal headache, visual disturbances, persistent abdominal pain in
right upper quadrant, chest pain or shortness of breath, suspected abruptio placentae, HELLP syndrome, intrauterine growth restriction, oligohydramnios, or
absent or reverse umbilical artery end diastolic flow, as detected by Doppler velocitometry. Chronic hypertension with superimposed preeclampsia was defined
as known chronic hypertension associated with further worsening of blood pressure and protein excretion ≥ 3 g/day after 20 weeks gestation. Non-preeclamptic
hypertensive disorders (criterion for exclusion as case or control) included gestational hypertension, defined as diastolic hypertension (≥ 90 mm Hg) that
developed after 20 wks gestation but without proteinuria or adverse conditions, and chronic known hypertension, defined as diastolic hypertension (≥ 90 mm
Hg) that predated pregnancy or was diagnosed before 20 wks gestation, with or without proteinuria.
b Early-onset preeclampsia defined as occurrence at < 34 weeks gestation [18]
c Severe preeclampsia defined as presence of any of the following: seizure, HELLP, proteinuria ≥ 3 g/24 hours or diastolic blood pressure > 110 mm Hg [18]
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age, pre-pregnancy BMI, maternal language other than
French or English, diabetes preceding or during preg-
nancy, chronic hypertension and parity (nullipara vs.
other).
All analyses were performed using SAS version 9.1
(SAS Institute, Cary, NC).
Results
Of the 20,830 women who were approached for partici-
pation in the study from 1999 to 2003, 5337 were
recruited and attended the 24-26-week study visit, and
thus comprised the study cohort (Figure 1). Of these,
175 did not deliver at a study hospital and were lost to
follow-up. Of 5162 study women followed to delivery,
113 developed preeclampsia (cases) (2.2%) (Table 1).
Subsequent to identification of cases, 443 controls were
chosen.
Characteristics of the study population are shown in
Table 2. Controls had very similar characteristics to all
non-cases (i.e. cohort women from among whom con-
trols were selected). Women with preeclampsia had
higher pre-pregnancy BMI than non-cases, were more
likely to have a history of diabetes, prior hypertension
and preeclampsia during a previous pregnancy and were
less likely to be current smokers.
Pregnancy outcomes are shown in Table 3. Cases with
preeclampsia were significantly more likely than controls
to deliver at earlier gestational age and to have a higher
incidence of SGA birth, with correspondingly lower
BWGA z-scores.
Maternal smoking and preeclampsia
Self-reported smoking and hair nicotine levels in cases
and controls are shown in Table 4. While results did
not achieve statistical significance, cases tended to be
less likely than controls to report smoking throughout
pregnancy (p = 0.07) or to report smoking steadily
within the same category of number of cigarettes
throughout pregnancy (p = 0.05). Cases also had lower
3583 ineligible* based on exclusion 
criteria in Methods 
11910 eligible but did not participate
x Refused: 5201 
x Undecided: 3636 
x Recruited but did not present 
for 24 week visit: 3073
175 lost to follow-up 
20833 approached for 
participation 
5337 recruited and had 24 
week study visit 
5162 delivered
Preeclampsia cases 
113
Controls
443
Gestational hypertension 
(ineligible to be case or control) 
117
Figure 1 Study flow diagram. * data on reasons for ineligibility were available in 952. The most common reasons were lack of fluency in
French or English (n = 321), plans to deliver in a non-study hospital (n = 272), severe chronic disease (n = 90) and gestational age at initial
contact > 24 weeks (n = 62).
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ing fewer cigarettes per day (p = 0.08) than controls.
Effect of smoking on fetal growth in controls
Among controls, mean (SD) BWGA z-score was lower
in self-reported smokers than in non-smokers (-0.26
(0.89) vs. 0.22 (0.96); p = 0.0002) and was lower in
women with hair nicotine levels above vs. below the
median (0.01 (0.99) vs. 0.30 (0.95); p = 0.004). Similarly,
the risk of SGA birth was significantly increased in self-
reported smokers vs. non-smokers (OR 2.28 [95% CI
1.01, 5.56]) and in women with hair nicotine levels
above vs. below the median (OR 5.36 [1.99, 14.40]).
Association between smoking, preeclampsia and fetal
growth
Consistent with the findings reported above, linear
regression analysis showed that self-reported smoking
Table 2 Comparison of preeclampsia cases, non-cases and controls: demographic, medical and obstetric characteristics
ascertained at 24-26 week study visit
Characteristic Cases
(n = 113)
Non-cases*
(n = 5107)
Controls
(n = 443)
Age category
< 20 years 3% 3% 3%
20-34 years 78% 79% 79%
> 34 years 19% 18% 18%
Hospital recruited
Hôpital St. Luc 15% 22% 24%
Hôpital Maisonneuve Rosemont 39% 36% 37%
Royal Victoria Hospital 22% 18% 17%
Jewish General Hospital 24% 24% 22%
Body Mass Index before pregnancy, kg/m
2
< 18.5 2% 8% 9%
18.5 to < 25 52% 63% 60%
25 to < 30 27% 18% 18%
≥ 30 19% 11% 13%
Primigravida 40% 35% 34%
Use of prenatal vitamins 92% 92% 92%
Diabetes before pregnancy or prior to 24 weeks gestation 6% 2% 1%
High blood pressure before pregnancy 8% 4% 3%
Previous preeclampsia or eclampsia (among women with prior pregnancy lasting > 20 wks) 21% 3% 3%
Smoke currently 10% 16% 16%
* Non-cases = study cohort (n = 5337) excluding cases (n = 113) and women who developed gestational hypertension without preeclampsia (n = 117).
Controls were selected from among non-cases as described under Methods.
Table 3 Gestational age and fetal growth among preeclampsia cases and controls
Cases Controls P value
Gestational age at delivery, weeks; mean (SD)* 36.8 (3.5) 39.2 (1.4) < 0.0001
Gestational age at delivery, weeks*
< 32 weeks 8 (7%) 1 (0%) < 0.0001
32-33 weeks 6 (5%) 0 (0%)
34-36 weeks 23 (21%) 18 (4%)
≥ 37 weeks 76 (67%) 415 (96%)
Birthweight, grams; mean (SD)
# 2834.4 (848.4) 3485.3 (500.2) < 0.0001
Z-score birthweight for gestational age^; mean (SD) -0.31 (1.0) 0.15 (0.9) < 0.0001
Small for gestational age^ 22 (21.6%) 32 (7.3%) < 0.0001
Large for gestational age^ 6 (5.9%) 50 (11.3%) 0.10
Z-score placental weight for gestational age
+;
mean (SD)
-0.01(1.13) 0.15 (0.98) 0.25
Values shown are n (%) unless otherwise noted
* data missing for 9 subjects;
# data missing for 5 subjects;
^ Z-score birthweight for gestational age, small for gestational age, large for gestational age as defined in Kramer et al [14]; data missing for 13 subjects
+ Z-score placental weight for gestational age calculated as defined by McNamara [15,16]; placenta data missing for 186 subjects
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BWGA z-scores (b = -0.29; p = 0.008, and b =- 0 . 6 7 ;p
< 0.0001, respectively). However, a significant positive
interaction was detected between smoking and pree-
clampsia (interaction term b = +0.86; p = 0.0008) such
that being a smoker decreased the BWGA z-score by
-0.29 in controls but increased it by +0.57 in preeclamp-
sia cases (Model 1a) (Table 5). In clinical terms, this
increase in z-score would translate into a 234 g heavier
weight for a male singleton born at 34 weeks, or a 255 g
heavier weight for a male singleton born at 38 weeks
[14]. Results were similar after adjustment for age, pre-
pregnancy BMI, maternal language other than French or
English, pre-gestational diabetes, chronic hypertension
and parity (nullipara vs. other) (Model 1a adjusted),
adjustment for PWGA (Model 1b), and adjustment for
all of the above (Model 1b adjusted) (Table 5).
Similar results were obtained when log hair nicotine
was substituted for self-reported smoking in the models
(Models 2a and 2b) (Table 5). For example, in Model
2a, an increase in log hair nicotine by 1 unit decreased
the BWGA z-score by -0.12 in controls, but increased
the BWGA z-score by +0.16 in preeclampsia cases (i.e.
bnic (log nicotine) + binteraction (log nicotine*pree-
clampsia) = -0.12*1 + 0.28 (1*0) = -0.12 for controls,
and -0.12*1 + 0.28 (1*1) = 0.16 for preeclampsia cases).
Due to the small numbers of smokers in subgroups of
cases with early onset preeclampsia and severe pree-
clampsia, we were unable to examine the association
between smoking, subtypes of preeclampsia and fetal
growth.
Levels of sFlt-1 in association with preeclampsia and
smoking
Mean (SD) plasma sFlt-1 was 761.5 (445.6) pg/ml in
preeclampsia cases and 703.83 (358.8) pg/ml in controls
(p = 0.21), and cases were more likely to have sFlt-1
concentrations in the top quartile of values than con-
trols (33.9% vs. 21.9%, p = 0.016). Among preeclampsia
cases, women with hair nicotine levels above the median
had significantly lower mean (SD) sFlt-1 levels than
women with hair nicotine levels below the median
(660.4 (377.2) pg/ml vs. 903.5 (466.4) pg/ml, respec-
tively; p = 0.0054) and tended to be less likely to have
sFlt-1 concentrations in the top quartile of control
values (29.4% vs. 44.7%, p = 0.16). Among controls, sFlt-
1 levels did not vary by hair nicotine level.
Discussion
We found that cigarette smoking was associated with
reduced fetal growth restriction in preeclamptic women.
This finding remained robust after adjustment for
potentially confounding covariates. We further found
that preeclamptic women who had higher levels of
exposure to smoking, indicated by higher hair nicotine
levels, had significantly lower plasma concentrations of
the circulating anti-angiogenic protein sFlt-1 at 24-26
weeks gestation than preeclamptic women with lower
levels of smoking exposure.
We also confirmed previous reports that smokers are
less likely to develop preeclampsia than non-smokers
and have lower birthweight for gestational age babies;
that high BMI, diabetes, hypertension, primigravidity,
previous preeclampsia and family history of preeclamp-
sia increase the risk of preeclampsia; and that fetal out-
comes are worse in preeclamptic vs. non-preeclamptic
women.
Our study has a number of strengths. Cohort women
were recruited prospectively and consecutively at four
large maternity hospitals in Montreal that serve a wide
socioeconomic and demographic spectrum and are likely
to be broadly representative of the general obstetric
population. While the incidence of preeclampsia in our
cohort (2.2%) was at the lower end of that previously
reported in healthy pregnant women [18], this likely
reflects our use of strict, high-specificity criteria to diag-
nose preeclampsia. We are confident that we did not
miss cases of preeclampsia as trained research assistants
Table 4 Self-reported cigarette smoking and hair nicotine levels in preeclampsia cases and controls
Variable Cases
N = 113
Controls
N = 443
p-value
Smoked throughout pregnancy 10 (8.9%) 69 (15.6%) 0.07
Smoked steadily (within the same category of number of cigarettes) throughout pregnancy 4 (3.4%) 41 (9.3%) 0.05
Average number of cigarettes/day, mean (SD)* 1.20 (3.6) 1.91 (4.7) 0.08
Category of average number of cigarettes smoked per day
0 90 (80.4%) 340 (77.3%) 0.69
1-10 16 (14.3%) 67 (15.2%)
>1 0 6 (5.4%) 33 (7.5%)
Hair nicotine (ng/mg), mean (SD)
# 1.29 (2.9) 1.94 (5.4) 0.10
Values shown are n (%) unless otherwise noted
* calculated as average of the number of cigarettes smoked per day in each of the trimesters.
# Hair nicotine available for 99 cases and 398 controls
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tain, using a detailed checklist, if criteria for preeclamp-
sia were met. Our success in obtaining “true” cases of
preeclampsia is shown by the differences in frequency of
recognized preeclampsia risk factors and indicators of
poorer pregnancy outcomes in cases and controls.
Results were similar whether we assessed smoking expo-
sure by self-report or using hair nicotine level, hence
misclassification of smoking exposure is unlikely [19].
We used hair nicotine rather than hair cotinine as a
measure of maternal tobacco smoke exposure because
previous work by our group found that hair nicotine
was a better predictor of reduced infant birthweight in
control women, and hence a better measure of maternal
smoke exposure [20]. The proportion of women who
reported smoking during pregnancy was similar to that
of other large cohorts of pregnant women [21,22]. We
assessed fetal growth on a continuous scale adjusted for
sex and gestational age, using Canadian population-
based standards [14].
As the sample size of our study was predetermined by
the requirements of the Montreal Prematurity Study,
Table 5 Linear regression analyses: Relationship between maternal exposure to smoking, preeclampsia and fetal
growth
Model Unadjusted b
(95% CI)
p-value Adjusted b
#
(95% CI)
p-value
Model 1a
z-score BWGA = smoker + preeclampsia + interaction term
Smoker -0.29
(-0.51,-0.08)
0.008 -0.38
(-0.61, -0.15)
0.0013
Preeclampsia -0.67
(-0.91,-0.43)
< 0.0001 -0.67
(-0.93, -0.41)
< 0.0001
Smoker* preeclampsia 0.86
(0.36, 1.36)
0.0008 0.86
(0.33, 1.39)
0.0015
Model 1b
z-score BWGA = smoker + preeclampsia + interaction term + z-score PWGA
Smoker -0.30
(-0.50, -0.09)
0.004 -0.32
(-0.54, -0.09)
0.0067
Preeclampsia -0.61
(-0.86, -0.35)
< 0.0001 -0.60
(-0.87, -0.33)
< 0.0001
Smoker* preeclampsia 0.74
(0.25, 1.23)
0.003 0.69
(0.16, 1.22)
0.0112
z-score PWGA 0.56
(0.48, 0.65)
< 0.0001 0.52
(0.43, 0.61)
< 0.0001
Model 2a
z-score BWGA = log hair nicotine + preeclampsia + interaction term
Log nicotine -0.12
(-0.16, -0.05)
0.0004 -0.086
(-0.16, -0.01)
0.0234
Preeclampsia -0.31
(-0.55, -0.07)
0.011 -0.36
(-0.63, -0.09)
0.0087
Log hair nicotine * preeclampsia 0.28
(0.11, 0.46)
0.002 0.26
(0.07, 0.46)
0.0091
Model 2b
z-score BWGA = log hair nicotine + preeclampsia + interaction term + z-score PWGA
Log nicotine -0.09
(-0.16, -0.03)
0.005 -0.06
(-0.13, 0.01)
0.0912
Preeclampsia -0.31
(-0.54, -0.08)
0.009 -0.33
(-0.60, -0.07)
0.0131
Log hair nicotine * preeclampsia 0.25
(0.07, 0.42)
0.007 0.25
(0.06, 0.44)
0.0095
z-score PWGA 0.56
(0.48, 0.64)
< 0.0001 0.52
(0.42, 0.62)
< 0.0001
Dependent variable for all models: z-score birthweight for gestational age (BWGA), as defined in Kramer et al [14]
PWGA = placental weight for gestational age; z-score PWGA calculated as defined by McNamara [15,16]
# analyses adjusted for age, pre-pregnancy body mass index, maternal language other than French or English, diabetes, chronic hypertension and parity
(nullipara vs. other). For adjusted models 1a and 1b, diabetes was statistically significant (p = 0.03 and p = 0.03, respectively). No other variables were statistically
significant in any of the models.
R-square for models: Model 1a unadjusted, 0.057, Model 1a adjusted, 0.096; Model 1b unadjusted, 0.388, Model 1b adjusted, 0.391; Model 2a unadjusted, 0.062,
Model 2a adjusted, 0.100; Model 2b unadjusted, 0.395, Model 2b adjusted, 0.384.
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between smoking and preeclampsia. Furthermore, we
could not perform analyses by preeclampsia subtype,
which would have been of interest as severe, early-onset
preeclampsia may be a different disease entity from
milder forms of preeclampsia [1]. We did not have
information on race/ethnicity of study women, hence
could not examine potential effects on BWGA z-score,
preeclampsia incidence or hair nicotine levels. Finally,
we acknowledge that associations should be considered
hypothesis-generating and do not prove causality.
Smoking has consistently been shown to reduce the
risk of preeclampsia by ~30% [2,3]. The biological
mechanism of this protective effect is uncertain, but
may relate to inhibitory effects of smoking by-products
such as nicotine and carbon monoxide on endothelial
dysfunction and excessive maternal inflammatory
response [6]. Nicotine acts on human placenta to release
placental acetylcholine, which stimulates release of
endothelium-derived relaxing factor and nitric oxide
[23], and in vitro studies show that nicotine selectively
inhibits thromboxane A2 synthesis [24]. Both effects
would be expected to reduce endothelial dysfunction
and preserve placental blood flow. Nicotine also has
anti-inflammatory activity and inhibits placental cyto-
kine production [4]. Carbon monoxide has direct pla-
cental effects that could reduce the risk of preeclampsia,
including promotion of trophoblast invasion, reduced
decidual inflammatory response, increased uteroplacen-
tal blood flow, decreased hypoxia-induced apoptosis and
upregulation of placental antioxidant systems [5,25].
Finally, findings of a recent Swedish birth register study
suggest that tobacco combustion products rather than
nicotine may be protective of preeclampsia, and it may
be the smoking habits in middle or late gestation (rather
than beginning of pregnancy) that influence the risk of
developing preeclampsia [26].
Our finding that smoking attenuated the relationship
between preeclampsia and fetal growth restriction is
intriguing, as some studies have reported a U-shaped
pattern of fetal growth in populations of women with
preeclampsia. In a population-based, retrospective Cana-
dian study, Xiong reported that women with preeclamp-
s i ah a da2 . 6 - f o l dh i g h e rr i s ko fS G Ab i r t ht h a n
normotensive women, but also had a 1.8-fold higher risk
of LGA birth [9]. While analyses controlled for self-
reported smoking, potential interaction between smok-
ing and preeclampsia on fetal growth was not examined.
Similar results were reported in a population of Chinese
women, for which information on maternal smoking
was not available [27]. Based on our finding that pree-
clamptic women who smoked had infants with higher
BWGA compared to preeclamptic women who were
non-smokers, we suggest that smoking may account, at
least in part, for the U-shaped pattern of fetal growth in
preeclampsia.
In our study, plasma sFlt-1 levels were significantly
lower in preeclamptic women with higher hair nicotine
levels. This suggests that smoking may attenuate fetal
growth restriction by reducing production of the anti-
angiogenic protein sFlt-1. sFlt-1 is secreted by the pla-
centa into the maternal circulation and adheres to the
receptor-binding domains of placental growth factor and
vascular endothelial growth factor (VEGF), preventing
interaction with endothelial receptors, blocking VEGF-
mediated vasodilation and inducing endothelial dysfunc-
tion [8], considered to be key to the pathogenesis of
preeclampsia [6]. Levels of sFlt-1 are elevated in pree-
clamptic women, and beginning at 21-24 weeks gesta-
tion, in pregnant women who subsequently develop
preeclampsia [7,8]. Smoking increases placental expres-
sion of VEGF [28], and plasma sFlt-1 levels have been
found to be decreased in smokers [29]. Furthermore,
carbon monoxide has inhibits sFlt-1 production in mice
[30]. This effect of smoking on increasing pro-angio-
genic factors and reducing anti-angiogenic factors may
explain why preeclampsia occurs less frequently in smo-
kers, and could also explain our finding that among pre-
eclamptic women, smoking limits fetal growth
restriction. A recent study of 58 preeclamptic women
also reported a tendency to lower sFlt-1 levels in smo-
kers vs. non-smokers [7].
Finally, our finding of a protective effect of smoking
on preeclampsia-associated fetal growth restriction cor-
roborates that of a recent linked record study of >
650,000 pregnancies, in which self-reported smokers
who developed preeclampsia had a lower adjusted mean
difference in birthweight compared to controls than
would have been expected based on the independent
additive effects of smoking and preeclampsia, and lower
than expected rates of preterm delivery [31]. Further-
more, a secondary analysis of the Calcium for Pree-
clampsia Prevention trial reported that among 274
nulliparous women with preeclampsia, smoking did not
act to further reduce infant birthweight, compared with
non-smoking women [32].
Conclusions
In conclusion, fetal growth restriction in preeclamptic
pregnancies seems to be attenuated by maternal smok-
ing. Smoking may account, at least in part, for the U-
shaped pattern of fetal growth described in women with
preeclampsia, and may exert this effect by reducing
levels of the anti-angiogenic protein sFlt-1. Further
exploration of the reasons why smoking may protect
against preeclampsia-associated fetal growth restriction
could increase understanding of the pathophysiology of
preeclampsia.
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